We demonstrate that, beyond targeting capabilities, bispecific DNA–peptide agents can also serve as platforms for payload delivery, enabling targeted cytotoxicity against cancer cells expressing EGFR and MET receptors. This evidence concerns the gene EGFR and cancer.